晚期软组织肉瘤对艾日布林应答的microRNA生物标志物鉴定:EORTC 62052试验的转化研究结果
本研究基于EORTC 62052 II期试验,收集65例晚期软组织肉瘤患者治疗前肿瘤组织,用Taqman低密度阵列检测756个microRNA表达,以12周无进展生存(RECIST 1.0)为应答指标。53例可评估患者中17例(32.1%)为应答者,发现26个microRNA在应答者与非应答者间表达差异显著(p<0.05)。作者认为特定microRNA可能预测艾日布林疗效,但需进一步验证及临床前机制评估。
要点
- 65例晚期软组织肉瘤患者治疗前组织检测756个microRNA,53例可评估,17例(32.1%)12周无进展。
- 26个microRNA在应答者与非应答者间表达差异显著(p<0.05)。
- 按组织学亚组分析发现其他可能相关microRNA;结论需进一步验证及临床前机制研究。
核心结论
- STS组织样本中特定microRNA的表达水平可能预测艾日布林应答。
- 需要进一步验证研究以及临床前评估潜在分子机制。
研究设计与样本
- EORTC 62052 II期试验(ClinicalTrials.gov NCT00413192)的探索性转化研究,纳入多种STS亚型。
- 收集65例同意患者艾日布林治疗前的原发或转移灶存档肿瘤组织。
- 组织来源包括21例平滑肌肉瘤、14例脂肪细胞性肉瘤、9例滑膜肉瘤和21例其他组织学类型。
- 从福尔马林固定石蜡包埋样本提取总RNA,用Taqman低密度阵列检测756个microRNA表达谱。
- 主要终点为12周无进展生存(RECIST 1.0),作为二分类变量用于相关性分析。
主要发现
- 53例可评估患者中17例(32.1%)在第12周无进展,定义为应答者。
- 26个microRNA在非应答者与应答者间表达差异显著(p<0.05)。
- 考虑不同组织学亚组时,识别出其他可能相关的microRNA。
局限性
- 需要进一步验证研究以及临床前评估潜在分子机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent phase II and III clinical trials demonstrated anti-tumour activity of eribulin, a tubulin-interacting cytotoxic agent, in patients with metastatic soft tissue sarcoma (STS). In this exploratory study, we aimed to identify putative microRNA biomarkers that associate with eribulin sensitivity or resistance in STS. MATERIALS AND METHODS: Archival tumour tissue from primary tumours or metastatic lesions was collected prior to eribulin treatment, from 65 consenting patients involved in the EORTC trial 62052. This phase II study (ClinicalTrials.gov identifier NCT00413192) included multiple subtypes of STS. Tissue was available from 21 leiomyosarcomas, 14 adipocytic sarcomas, 9 synovial sarcomas and 21 other sarcoma histotypes. Total RNA was isolated from formalin-fixed, paraffin-embedded tumour samples and analysed using Taqman® Low Density Arrays to determine microRNA expression profiles. The expression of a total of 756 microRNAs was assessed. Progression-free survival at week 12 (RECIST 1.0) measured as a binary variable, was the primary end-point of the clinical trial and used as a primary response measure for correlative studies. Seventeen of 53 (32.1%) evaluable patients in the analysed subset had non-progressive disease at week 12 and were defined as responders. RESULTS: The expression of 26 individual microRNAs (p < 0.05) differed significantly between non-responders and responders. Additional microRNAs of potential relevance were identified when considering the different histological subgroups. CONCLUSIONS: The expression level of particular microRNAs in STS tissue samples may predict response to eribulin. Further validation studies as well as a preclinical assessment of the underlying molecular mechanisms are required.
引用
- Wiemer EAC, Wozniak A, Burger H, et al. Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial. Eur J Cancer. 2017. PMID: 28214655. doi:10.1016/j.ejca.2016.12.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。